SCHEMBL3774256

SCHEMBL3774256

O=C(CN1CCN(C(=O)c2cccnc2)CC1)N1CCN(C2CCC2)CC1

nearest known ligand 0.59

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.59
TRPV6 Q9H1D0 1/20 0.55
KDM4E B2RXH2 5/20 0.51
MAPK1 P28482 1/20 0.51
FABP6 P51161 1/20 0.51
HRH3 Q9Y5N1 2/20 0.51
POLB P06746 2/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
ALOX15 P16050 1/20 0.49
GAA P10253 1/20 0.48
PKM P14618 1/20 0.48
CYP3A4 P08684 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3769040 0.87 KDM4E (0.67) ALDH1A1TRPV6KDM4EHRH3POLB
SCHEMBL3770368 0.86 KDM4E (0.67) ALDH1A1KDM4EHRH3POLB
SCHEMBL31329763 0.84 PKM (0.60) ALDH1A1TRPV6KDM4EMAPK1POLB
SCHEMBL3767275 0.83 L3MBTL3 (0.66) ALDH1A1KDM4EHRH3SMN1; SMN2GAA
SCHEMBL3771962 0.82 HRH3 (0.54) ALDH1A1TRPV6KDM4EMAPK1HRH3
SCHEMBL3767528 0.81 HRH3 (0.53) HRH3SMN1; SMN2
SCHEMBL13005977 0.81 KDM4E (0.46) ALDH1A1KDM4EHRH3POLB
SCHEMBL3774042 0.80 HRH3 (0.49) HRH3
SCHEMBL3767284 0.80 KDM4E (0.70) ALDH1A1KDM4EHRH3CYP2C19
SCHEMBL3769162 0.80 HTT (0.70) ALDH1A1KDM4EHRH3POLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 ALDH1A1 1210/4885TRPV6 1375/4885KDM4E 534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.